Drugs

Trastuzumab Product Approval Information - Licensing Action 9/25/98

Proper name: Trastuzumab
Tradename: Herceptin
Manufacturer: Genentech, Inc, South San Francisco, CA, License #1048
Indication for Use: Treatment of patients with metastatic breast cancer whose tumors overexpress the HER2 protein and who have received one or more chemotherapy regimens for their metastatic disease. Trastuzumab in combination with paclitaxel is indicated for treatment of patients with metastatic breast cancer whose tumors overexpress HER2 protein and who have not received chemotherapy for their metastatic disease
Approval Date: 9/25/98
Type of submission: Biologics license application


Approval Letter (PDF)

Label (PDF) (oversize document; if printing, use 'shrink to fit')

Review Documents

Biopotency Review (PDF)

Clinical Review

CMC Review (PDF)

Pharmacology Review (PDF)

Statistical Review (PDF)

Page Last Updated: 12/18/2015
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English